1 1 HLA-LINKED CONGENITAL ADRENAL HYPERPLASIA RESULTS FROM A DEFECTIVE GENE ENCODING A CYTOCHROME P-450. Congenit a1 adrenal hyperpl a s i a due t o 21-hydroxyl ase (21-OH) d e f i c i e n c y i s HLA-linked. The haplotype HLA-(A3) ;Bw47;DR7 i s s t r o n a l v associated w i t h 21-OH d e f i c i e n c v and alwavs c a r r i e s a n u l l a l i e l e a t t h e complement C4A (~o d g & s ) l o c u s . -I t seemed l i k e l y t h a t t h i s haplotype c a r r i e s a d e l e t i o n encompassing both t h e C4A and 21-OH l o c i . We hypothesized t h a t t h e HLA-linked def e c t involved a s t r u c t u r a l gene f o r t h e adrenal microsomal c y t ochrome P-450 s p e c i f i c f o r s t e r o i d 21-hydroxylation. We i s o l a t e d a plasmid w i t h a 520 bp bovine adrenal cDNA i n s e r t encoding t h e middle t h i r d o f t h e P-450 peptide [White e t a1 . PNAS A p r i l 19841.
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When human DNA was digested w i t h Taq I r e s t r i c t i o n endonuclease and h y b r i d i z e d w i t h t h e cDNA probe, DNA from 13 unrelated normal i n d i v i d u a l s y i e l d e d two h y b r i d i z i n g bands o f equal i n t e n s i t y a t 3.7 and 3.2 kb. The upper band was not present i n DNA from a pat i e n t homozygous f o r Bw47. DNA from s i x u n r e l a t e d p a t i e n t s heterozygous f o r Bw47 yielded, i n f i v e , diminished r e 1 a t i v e i n t e n s i t y o f t h e upper band c o n s i s t e n t w i t h a heterozyqous d $ l e t i o n , and complete disappearance o f t h e upper band i n one ( X =15.9, p=.0001). Linkage o f t h i s polymorphism t o HLA was examined i n t h e f a m i l i e s o f several o f these p a t i e n t s ; t h e l o d score exceeds 3.0 at a recombinant f r a c t i o n o f 0.0. Thus 21-OH d e f i c i e n c y sometimes r e s u l t s from t h e d e l e t i o n o f a gene and sometimes, presumably, from smaller mutations. This gene i s probably l o c a t e d very near t h e C4A gene encoding t h e 4 t h component o f complement. The existence of a salt-excreting factor in CAH due to a 21-hydroxylase defect has been postulated for many years.However extensive investigations sofar were unable to isolate such a factor.0ur demonstration of a salt-excyeting factor in CAH utilized direct and indirect measurements of the minera1ocorticoidactivity.The direct method was based on the ability of mineralocorticoid agonists and antagonists to displace aldosterone in a mineralocorticoid radioreceptor assay.The indirect method measured the separate contributions of the principal mineralocorticoid agonists:aldosterone, 11-deoxycorticosterone,corticosterone and cortisol as determined from their relative receptor affinity. In controls there was good agreement between these two measurements.However,when plasma extracts from patients with CAH were assayed, the direct method showed almost twice as much activity as the indirect method. This difference in mineralocorticoid receptor activity was observed in both the salt-wasting and the non-salt-wasting form and was suppressed by dexamethasone and restored by ACTH. We propose that this difference results from the presence of a mineralocorticoid antagonist which competes with the known agonists for the mineraloaortieoid receptor. In salt-wasting CAH this antagonist may contribute to salt-wasting symptoms:in the simple-virilizing form this antagonist may cause hyperreninemia and hyperaldosteronism. Effects of ACTH and oestradiol on steroid production by cultured adrenal cells from an anencephalic foetus and from normal adults.
Dispersed adrenal cells from a 16 week anencephalic foetus, 7 foetuses with intact pituitaries and 3 adult subjects at the time of renal transplantation were maintained in tissue culture for 6 days and the steroidogenic responses to ACTH (0-13~ pg/ml) with or without added oestradiol (0-lo4 ng/ml) were evaluated. The anencephalic cells showed a delayed response to ACTH but by the fifth day production of cortisol (1 pg per lo5 cells per day), dehydroepiandrosterone (DHA) and DHA-sulphate was similar to that in the other cultured foetal adrenal cells. The addition of oestradiol caused dose-related inhibition of cortisol production and concomitant increase in DHA and DHA-sulphate production. The adult adrenal cells in the presence of ACTH showed a much higher cortisol-DHA secretion ratio (on average 60-hold higher) but the addition of oestradiol markedly reduced this ratio as in foetal cells. These data support the suggestion that the relative 3p-hydroxysteroid dehydrogenase deficiency characteristic of the foetus is not an intrinsic property of foetal adrenal cells but is imposed by the combined effects of ACTH and steroids within the foetal environment (such as oestradiol).
Increased mortality with long-term E infusions in intensive care patients has been reported and evidence is accumulating that E causes reversible adrenocortical suppression with decreased serum cortisol levels. A direct inhibition of adrenal steroidogenesis has been suggested, but so far data on the mechanism of this action are lacking. A 6 1/2 year old boy with convulsions due to encephalitis was treated with constant E infusions (1 -2 mg/kg/h) . Prior to E administration, adrenocortical function was normal as tested by an ACTH-test. 5 days after institution of therapy and 14 days after discontinuation, plasm levels of 11-deoxycorticosterone (DOC), corticosterone (B) , 11-deoxycortisol (S) and cortisol (F) were measured by RIAs after Sephadex LH-20 chromtography. During E therapy DOC and S levels were highly elevated, while B was in the lower normal range and F was m k e dly decreased. Likewise the ratios of B/DOC and F/S, which reflect adrenocortical 11 B-hydroxylase activity, were extremely decreased (B/DOC:0.06 vs 27 in controls; F/S:0.009 vs 230 i n controls). After discontinuation of therapy, the absolute values as well as the ratios returned to n o m l . These results show, that E is a potent inhibitor of adrenal 11 5-hydroxylation.1ncreased precaution seems to be necessary when this drug is used in patients who are under considerable amount of stress. Two female newborns (NO1 & 2), a 13-yr girl (N03) (stages 11-IV) and a 2 y r boy (N04) were studied. 11%-OHD was ascertained on elevated levels of plasma 11-deoxycortisol (S) or urinary THS. Plasma levels (in nmol/l) of A ' , testosterone (T)and 17a-OH-progesterone (OHP) were followed before, at, and during replacement therapy (Rx),after ACTH (1 mg/m2/dx3) or Dex (2 mgIdx8).
Before Rx, A ' (33 to 297) was always higher than O W . The molar A4/0~P ratio was constantly high (2.7 + l.l;n=lO), in contrast to patients with 21-OHD in whom this rat& is -0.03 (0.009 to 0.5). In case No I, OHP was subnormal at 2-27 days of age; 11%-OHD was suspected only on a high (2-4)A4/0~P ratio; after ACTH,A~ rose drastically (34.4 to 144), more than OHP(8.6 to 66) and A'/OW remained similar (2.2).Under Dex (case N04),0HP dropped to normal within 24 h, while A4 decreased slowly and remained abnormally high (5.9) on day 8,thus a stricking rise in A4/0~p (2.2 to 18-32) occured during the test. The same pattern was seen in all cases at initiation of Rx. Diurnal variations were larger for OHP(4-10 fold than for A4(2-3 fold). Under long-term Rx(2-10 yr),despite low normal OHP, T was still above normal when A~O H P was >1. In conclusion, 1)there is a selective accumulation of A4in 11%-OHD which is likely due to the impaired metabolism of A4into 11%-OH A4(normal inactivation pathway) providing an increased substrat for peripheral T conversion. 2)A4/0~P is as useful as plasma S,and probably more sensitive,in monitoring Rx and should ideally be < 1. Hormonal measurements and HLA genotyping of mniotic fluid st midgestation correctly predicted the ostnatal dx of CAH in 26 of 29 fetuses at risk for CAH. Of these 26, 6 were p r e h h a v e classical 21-OH def based on elevated mniotic fluid 17-hydroxyprogesterone (17-P) and44-androstenedione (A). These 6 fetuses and their index cases were ultimately proven to have salt wastin classical 21-OH def. Of 3 HLA typed, genotype was identical to the i n X i % Z T & a l mniofic fluid 17-P and A in the remaining 20 predicted fetuses unaffected wlth classical CAH, and these patients have been clinicallv asmotomatir t.n date nr hinehamirallv proven not to bk effected with classical or'n~&l&iicii~~AH.~Of~ti~ Ii-feEus;i;-6
were HLA typed and predicted to be homozvtlous unaffected or heterozvoous. However.
~------in 3 of the 29 fetuses, prenatal diaqnosis was incorrect. In one, kg;-f;t"swas-L predicted to have CAH based on HLA ldentlty to the index case. but mniotic fluid 17-P and A were normal and the fetus was normal. The index c&e of this fmily did not have CAH but was a normal child. Thus, mniotic fluid hormone levels accurately predicted a normal fetus while HLA typing was not relevant in prenatal dx because the index case was unaffected. The second fetus was predicted to be a carrier on the basis of HLA typing and normal mniotic fluid 17-P and A. However during infancy the female infant was shown to have nonclassical CAH and be HLA identical to the index case. The index case in this fmily, presuned to have classical CAH, was later diagnosed to have nonclassical CAH. In the third case the fetus was predicted to be a heterozygote by HLA genotyping and to be unaffe6ted by hormonal measurement. Postnatally, at age 2 7/12 yrs the male child was shorn to have non-salt-losin classical CAH and to be MA idekical to the index case vho also has non-salt-king CAH.
These data demonstrate that in salt-losing classical CAH, prenatal dx of the hmomozygous affected fetus is reliable by the measurement of mniotic fluid 17-P and A. In nonclassical or non-salt-losing classical CAH, mniotic fluid 17-P and A are in the normal range, thus prenatal dx is not possible by hormonal evaluation. Path homonal and HLA studies of fetal mniotic fluid, as well as correct dx of the specific form of 21-OH def and HLA studies of the index case, are essential in diagnosing the specific form of 21-OH def CAH in the fetus.
